Gaya Herald

NF-Kappa B Inhibitors Pipeline Insight, 2022 | Key Insights Into the Emerging Products, Key Companies, Latest Trends, Key Developments, and Evolving Competitive Landscape

 Breaking News
  • No posts were found

NF-Kappa B Inhibitors Pipeline Insight, 2022 | Key Insights Into the Emerging Products, Key Companies, Latest Trends, Key Developments, and Evolving Competitive Landscape

November 30
05:21 2022
NF-Kappa B Inhibitors Pipeline Insight, 2022 | Key Insights Into the Emerging Products, Key Companies, Latest Trends, Key Developments, and Evolving Competitive Landscape
DelveInsight Business Research LLP
As per DelveInsight’s assessment, globally, about 10+ key pharma and biotech companies are working on 10+ pipeline drugs in the NF-Kappa B Inhibitors therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

NF-Kappa B Inhibitors Pipeline Insight, 2022” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the  NF-Kappa B Inhibitors Market. 

The NF-Kappa B Inhibitors Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

NF-Kappa B Inhibitors Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into emerging therapies in the NF-Kappa B Inhibitors Market and the aggregate therapies developed by major pharma companies.
  • It accesses the different NF-Kappa B Inhibitors therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development.
  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the NF-Kappa B Inhibitors Market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Learn How the Ongoing Clinical & Commercial Activities will Affect the NF-Kappa B Inhibitors Therapeutic Segment @

NF-Kappa B Inhibitors Therapeutics Landscape

NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumor genesis, and apoptosis.

Due to the various levels of regulation, the NF-κB signaling pathway can be potentially targeted at various levels, including kinases, phosphatases, ubiquitination, nuclear translocation, DNA binding, protein acetyltransferase, and methyl transferases. The development of inhibitors specifically targeted to the NF-κB signaling pathway is a more recent endeavor.

Globally, there are approx. 10+ key companies which are developing NF-Kappa B Inhibitors based therapies. Currently, Merck has its NF-Kappa B Inhibitors drug candidates in the most advanced stage of clinical development.

NF-Kappa B Inhibitors Drugs Covered in the Report Include:

  • MK-7110: Merck
  • NE3107: NeurMedix
  • AMG 0101 (NF-κB Decoy Oligodeoxynucleotide): AnGes
  • CXA-10: Complexa
  • Imx-110: Immix Biopharma
  • AMG 0101: AnGes
  • NE 3107: NeurMedix
  • GLS-1027: GeneOne LifeScience
  • LH 025: Link Health Group
  • FW 424: First Wave Bio
  • ACT001: Accendatech

And many more

The Leading Companies in the NF-Kappa B Inhibitors Therapeutics Market Include:

Merck, NeurMedix, Complexa, GeneOne Life Science, Accendatech, Link Health Group, Immix Biopharma, First Wave Bio, IMMD, ILIAS Biologics, AnGes, NeurMedix, GeneOne LifeScience, Link Health Group, First Wave Bio, Accendatech, and many others.

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. NF-Kappa B Inhibitors Current Treatment Patterns

4. NF-Kappa B Inhibitors – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. NF-Kappa B Inhibitors Late Stage Products (Phase-III)

7. NF-Kappa B Inhibitors Mid-Stage Products (Phase-II)

8. NF-Kappa B Inhibitors Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. NF-Kappa B Inhibitors Discontinued Products

13. NF-Kappa B Inhibitors Product Profiles

14. Key Companies in the NF-Kappa B Inhibitors Market

15. Key Products in the NF-Kappa B Inhibitors Therapeutics Segment

16. Dormant and Discontinued Products

17. NF-Kappa B Inhibitors Unmet Needs

18. NF-Kappa B Inhibitors Future Perspectives

19. NF-Kappa B Inhibitors Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States